Count | |
| 2 | |
| 9 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
Neurofibromatoses/*classification/complications/*genetics/pathology | 1 |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
Promoter Regions (Genetics)/drug effects/*genetics/physiology | 1 |
Trans-Activation (Genetics)/drug effects/genetics/*physiology | 1 |
Promoter Regions (Genetics)/drug effects/genetics/physiology | 8 |
Promoter Regions (Genetics)/drug effects/genetics/*physiology | 4 |
Trans-Activation (Genetics)/drug effects/genetics/physiology | 1 |
Promoter Regions (Genetics)/drug effects/genetics/immunology | 1 |
| 8 | |
| 31 | |
| 5 | |
| 1 | |
| 18 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
Antisense Elements (Genetics)/genetics/metabolism/*pharmacology | 1 |
| 5 | |
| 4 | |
| 4 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 27 | |
| 2 | |
| 11 | |
| 2 | |
| 1 | |
| 7 | |
| 5 | |
| 3 | |
| 19 | |
| 5 | |
| 1 | |
| 1 | |
| 2 | |
| 5 | |
| 86 | |
| 1 | |
| 4 | |
| 68 | |
| 68 | |
| 2 | |
| 1 | |
| 1 | |
| 3 | |
| 11 | |
| 1 | |
| 2 | |
| 3 | |
| 1 | |
| 1078 | |
| 86 | |
| 822 | |
| 2 | |
Trans-Activation (Genetics)/drug effects/*genetics/radiation effects | 1 |
| 270 | |
| 225 | |
| 267 | |
| 4 | |
| 3 | |
| 166 | |
| 1 | |
| 4 | |
| 5 | |
| 2 | |